In 2013, the Food and Drug Administration banned 23andMe from marketing their genetic health reports, stating that the company had failed to provide evidence that the tests were "analytically or clinically validated." At that time, the company provided “risk assessments” for 254 genetic conditions. The company relaunched their health service in 2015, after scaling back to fewer conditions, with “health predisposition,” “carrier status,” and “wellness reports” replacing previous risk assessments.